Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11226 - 11250 of 12702 in total
LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. The implant is being developed clinically...
Investigational
Matched Description: … The implant is being developed clinically for the prevention of rejection in corneal transplantation. ... LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in
Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).
Investigational
Matched Description: … Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. …
XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied...
Investigational
Matched Description: … the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for...
Investigational
LY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. LY2181308 is known to target baculoviral IAP repeat-containing protein 5. LY2181308 is an anti-sense oligonucleotide that potently downregulated survivin expression in human cancer cells derived from lung,...
Investigational
Matched Description: … LY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. ... LY2181308 is an anti-sense oligonucleotide that potently downregulated survivin expression in human cancer …
LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.
Investigational
Matched Description: … LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of …
ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects. ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.
Investigational
Matched Description: … ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor …
ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.
Investigational
Matched Description: … ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and …
QR-334 is under investigation for the treatment of sialorrhea. Sialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling. No pharmaceutical interventions currently exist to treat sialorrhea. The symptom is associated with many diseases including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease,...
Investigational
Matched Description: … Sialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling. …
FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.
Investigational
Matched Description: … FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development …
R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and tumor cells. It is expected to be topical treatment for cervical displasia and cervical high-risk human papillomavirus (HPV), the sexually...
Investigational
Matched Description: … R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate …
VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma. Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.
Investigational
Matched Description: … Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in
Investigational
Investigational
SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features. SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that...
Investigational
Matched Description: … SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. ... traditional chemotherapeutics with no overt toxicity at doses one million times higher than effective doses in
A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome...
Investigational
Matched Description: … This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs ... X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in
XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.
Investigational
Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Investigational
Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.
Investigational
Matched Description: … Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, ... It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. …
MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults and children. Research on AFP suggests that it may play a role in modulating the immune system of...
Investigational
Matched Description: … Research on AFP suggests that it may play a role in modulating the immune system of the mother in order ... low levels in the blood of adults and children. ... ), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in
Pegteograstim is under investigation in clinical trial NCT02787876 (Pegteograstim in Children With Solid Tumors).
Investigational
Matched Description: … Pegteograstim is under investigation in clinical trial NCT02787876 (Pegteograstim in Children With Solid …
Dexamethasone isonicotinate is an anti-inflammatory, anti-allergic glucocorticoid that can be administered orally, by inhalation, topically, and parenterally. Its unintended mineralocorticoid action may cause salt and water retention.
Vet approved
Matched Categories: … Fused-Ring Compounds …
Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients).
Investigational
Matched Description: … of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant ... Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety …
rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.
Investigational
AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia for patients experiencing acute pain episodes. AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain.
Investigational
Matched Description: … AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain. …
Displaying drugs 11226 - 11250 of 12702 in total